- Home
- CATO vs IMA Comparison
CATO vs IMA Comparison
Compare CATO & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | IMA |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.8M | 65.4M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | CATO | IMA |
|---|---|---|
| Price | $3.02 | $6.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 54.2K | 45.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $649,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $5.70 |
| 52 Week High | $4.92 | $17.50 |
Technical Indicators
Market Signals| Indicator | CATO | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 49.83 |
| Support Level | $3.01 | $6.65 |
| Resistance Level | $3.22 | $7.17 |
| Average True Range (ATR) | 0.16 | 0.39 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 50.35 | 32.25 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.